Efficacy, safety and cost of ultrafiltration for the management of acute decompensated heart failure.

Pan I, Dendukuri N
Record ID 32010001378
English, French
Authors' objectives:

Evaluate the evidence of the efficacy, safety, and cost of the proposed intervention.

Authors' recommendations: There is sufficient evidence to conclude that ultrafiltration is an effective technology for the management of acutely decompensated heart failure.UF is the method of choice when patients have become resistant to diuretics or have developed secondary renal failure.On the basis of several assumptions for which the evidence is insubstantial, it is estimated that the cost of treating 50 diuretic resistant cases by UF instead of standard care, might have a net budget impact of $20,000 per year. [Note however, that this estimate is uncertain. The annual budget impact might be as great as $107,000, or there might be a savings of up to $76,000.]There is limited evidence that ultrafiltration may have long-term health benefits including improved exercise performance for up to three, and possibly six months, and that these effects are associated with a reduction in rehospitalization rates.
Details
Project Status: Completed
Year Published: 2010
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Canada
MeSH Terms
  • Costs and Cost Analysis
  • Ultrafiltration
Contact
Organisation Name: Technology Assessment Unit of the McGill University Health Centre (MUHC)
Contact Address: Technology Assessment Unit of the MUHC, 536-5100 Boul. Maisonneuve O, Montreal, H4A 3T2
Contact Name: eva.suarthana@mcgill.ca
Contact Email: nisha.almeida@muhc.mcgill.ca
Copyright: Technology Assessment Unit of the McGill University Health Centre (MUHC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.